24 aug: Mærsk: Havnerival leverer lidt lavere bundlinje i første halvår
24 aug: STG Q2: Faldende omsætning og overskud - forventninger fastholdt
24-08-2017 08:15:28

AroCell AB: Interim report, Q2 2017

Relateret indhold

   

AroCell AB (publ)

Reporting period 1 April - 30 June 2017

  • Net sales were 237 (0) KSEK

  • Losses after financial items were - 3,606 (- 1,962) KSEK

  • Earnings per share were - 0.27 (- 0.17) SEK

  • Cash flow from operating activities was - 3,163 (- 1,229) KSEK

  • Cash flow from investing activities was - 318 (- 1,800) KSEK

Interim report, 1 January - 30 June 2017

  • Net sales were 293 (0) KSEK

  • Losses after financial items were - 7,831 (- 4,804) KSEK

  • Earnings per share were - 0.27 (- 0.17) SEK

Revenues and expenses April - June 2017 (2016) KSEK

Sales for the period were 237 (0). Expenses were 3,771 (1,962). Taking into account capitalization of R&D, total expenses for the same period in 2016 amounted to 3,762. As the product has been fully developed and CE-marked, R&D expenses are no longer capitalized. According to plan marketing and sales expenses have increased which reflects our ambition to get TK 210 ELISA test to the market. Total cash flow for the period was -3,531 (-3,029). Cash at the end of the period was 24,423.

Revenues and expenses January - June 2017 (2016) KSEK

Sales for the period were 293 (0). Expenses were 8,052 (4,804). Taking into account capitalization of R&D, total expenses for the same period in 2016 amounted to 9,824. As the product has been fully developed and CE-marked, R&D expenses are no longer capitalized. According to plan marketing and sales expenses have increased which reflects our ambition to get TK 210 ELISA test to the market. Total cash flow for the period was -8,429 (-7,521). Cash at the end of the period was 24,423.

AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through Jan Stålemark, at 08:15 CET on 24 August 2017.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the rate of cell turnover. A tumor has high cell turnover (rate of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategies. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.

CEO Comments

As a result of our increased commercial activities we have begun to receive the first commercial orders from customers which is encouraging. The increase in the interest of our TK 210 ELISA test comes from pharmaceutical companies, IVD (in vitro diagnostic) companies as well as academic research groups. The key point of interest is that TK 210 ELISA is unique and the only CE marked IVD test for measuring TK 1 protein concentrations on the market. The AroCell team has been actively promoting TK 210 ELISA with potential customers in the US, Europe and Asia to identify future business opportunities. Recently a road tour has taken place in Japan and valuable contacts established.

The clinical validation remains a priority to ensure customer acceptance and long term growth. We have made good progress in the clinical development plan and we are excited about the first results which have been submitted for publication. The biomarker data specific to TK 210 ELISA from the Swedish Promix multicentre study has been submitted for presentation at a scientific meeting towards the end of this year. We will be able to share these results when they have been accepted for publication.

The second half of the year will be focused on further increasing customer interactions and identifying new opportunities for using TK 210 ELISA in clinical practice. There is also a focus on the R&D program to provide further data to support the clinical use of TK 210 ELISA.

Jan Stålemark

CEO

Essential risks

Financial risks

AroCell's business activities are based on external financing. To date, the company has been successful in obtaining financing, but there are not guarantees of this happening in the future in a way that is advantageous to the company's shareholders. A sufficiently serious failure in future financing may affect the company's development and market value.

Development and production risks

Development and transfer to production are always associated with risks. A product manufactured at production scale does not always display the same characteristics as one manufactured at research scale. Developing future products may also prove to be more complicated and take longer than expected.

Commercialization risks

There is always a risk that the products AroCell has developed will not achieve the expected positive reception on the market and that the product will need longer time to gain acceptance. Particularly in the early stages, the quantity of products sold may then be lower and the time it takes to establish the product on the market may be longer than the company allowed for in its sales estimates.

Currency risks

The company expenses are partially based in Euro, and this means that there is a risk that weakening of the Swedish krona against the Euro may lead to increased expenses for the company. A portion of the sales proceeds in future can be associated with currencies from other countries, which means that there is a risk that if the Swedish krona becomes stronger to other currencies, this may lead to decreased profits for the company in SEK.

In addition, there are risks associated with patent security and how the market assesses studies, approvals and certifications. Taking risk factors into consideration in decision processes and when designing routines and drawing up documentation means that the risks are assessed and their effects can be minimized, and to some extent, avoided.

The share

AroCell AB (publ) was listed on Nasdaq First North, Stockholm, June 30 2016 under AROC.

On March 31, 2017 there were 28 674 506 shares (quota value SEK 0.10).

Accounting principles

This Interim Report has been prepared in accordance with the Swedish law: Årsredovisningslagen and Bokföringsnämndens allmänna råd BFNAR 2012:1 Årsredovisning och Koncernredovisning (K3).

Report review

This interim report has not been reviewed by the companys auditor.

C

ontact information

Jan Stålemark VD                                                         AroCell AB (publ)

jan.stalemark@arocell.com                                           Virdings allé 32B

0706-92 62 06                                                                754 83  UPPSALA

www.arocell.com                                                           SVERIGE

Financial Calender

11/22/2017  Interim report 3 - 2017

02/22/2018  Interim report 4 - 2017

04/25/2018  Interim report 1 - 2018

08/23/2018  Interim report 2 - 2018

Submission of interim report

Uppsala August 23, 2017

The board of directors

Summary Income statement

     
(TSEK)

2017

2016

2017

2016

2016

 

Apr-Jun

Apr-Jun

Jan-Jun

Jan-Jun

Jan-Dec

 

3 mths

3 mths

6 mths

6 mths

full year

Net sales 237 - 293 - 59
Cost of goods sold -72 - -72 - -
Selling expenses -1,494 -968 -3,682 -2,394 -5,020
Administrative expenses -807 -625 -1,688 -1,343 -2,193
Research and development expenses -1,470 -369 -2,682 -1,067 -2,075

Operating loss

-3,606

-1,962

-7,831

-4,804

-9,229

Net financial items      -6
Loss after financial items

-3,606

-1,962

-7,831

-4,804

-9,235

Loss for the period

-3,606

-1,962

-7,831

-4,804

-9,235

      
      

Summary balance sheet

     
(TSEK)   

2017

2016

2016

   

Jun 30

Jun 30

Dec 31

ASSETS

     
Fixed assets      
Intangible assets    31,328 26,830 31,328
Tangible assets    475 11 170
Financial assets    50

-

-

Total fixed assets

  

31,853

26,841

31,498

Current asset      
Inventories    2,243 1,419 1,419
Other receivables    663 682 652
Cash and cash equivalents    24,423 42,181 32,852

Total current assets

  

27,329

44,282

34,923

Total assets

  

59,182

71,123

66,421

      

EQUITY AND LIABILITIES

     
Share capital    2,867 2,867 2,867
Restricted reserves    9,518 - 9,518
Other contributed capital and reserves    102,615 69,824 102,615
Non-restricted equity    -59,376 -4,804 -51,544

Total equity

  

55,624

67,887

63,456

Current liabilities    3,558 3,236 2,965

Total equity and liabilities

  

59,182

71,123

66,421

      
      

Summary cash flow statement

     
(TSEK)

2017

2016

2017

2016

2016

 

Apr-Jun

Apr-Jun

Jan-Jun

Jan-Jun

Jan-Dec

 

3 mths

3 mths

6 mths

6 mths

full year

Cash flow from operating activities -3,163 -1,229 -8,061 -2,501 -7,168
Cash flow from investing activities -318 -1,800 -318 -5,020 -9,682
Cash flow from financing activities -50 0 -50 0 0

Cash flow from the period

-3,531

-3,029

-8,429

-7,521

-16,850

Cash and cash equivalents at beginning of period 27,954 45,210 32,852 49,702 49,702

Cash and cash equivalents at end of period

24,423

42,181

24,423

42,181

32,852

Share data

     
   

2017

2016

2016

   

Jan-Jun

Jan-Jun

Jan-Dec

Earnings per share (SEK)      
Before dilution    -0.27 -0.17 0.32
After dilution    -0.27 -0.17 0.32
      
      
Average number of shares    28 674 506 28 674 506 28 674 506
           
      
           
           
           

Interim report, Q2 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: AroCell AB via Globenewswire

Vedhæftet fil: Interim report, Q2 2017.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Vindindustriens reaktion på prispres vil være i fokus på konference

21-11-2017 15:30:19
Vindmølleindustriens reaktion på prispresset afledt af overgangen til auktionsbaserede systemer vil være i fokus, når den europæiske vindmølleforening, Windeurope, 28-30. november holder konference i Amsterdam.Det vurderer Jacob Pedersen, aktieanalysechef i Sydbank, over for Ritzau Finans.- Prisudviklingen og det pres, det kommer til at skabe hele vejen ned i værdikæden i forhold til at opføre vin..

Novo/CEO: Effekt skal skærme tabletmiddel mod prispres

21-11-2017 12:24:46
Det handler om effekt, når Novo skal sikre, at selskabet ikke fanges i det prispres, der har ramt markedet for diabetesmedicin i tabletform.Det siger administrerende direktør i Novo Nordisk Lars Fruergaard Jørgensen tirsdag på selskabets kapitalmarkedsdag.Novo er i færd med at udvikle diabetes 2-midlet Semaglutid i tabletform og står dermed på spring til et kæmpe marked for tabletbehandling af typ..

Aktier/middag: C20 falder trods fremgang til Mærsk og Novo

21-11-2017 11:16:39
Størstedelen af de danske eliteaktier er i bakgear tirsdag formiddag, hvor C20 Cap-indekset falder med 0,1 pct. til 1123,30.Generelt er udsvingene ikke ret store, efterhånden som regnskabssæsonen er ved at nå sin afslutning.I stedet fokuserer investorerne blandt andet på udfaldet af forhandlingerne om den amerikanske skatteaftale, hvor Senatet snart skal stemme sit bud igennem, hvorefter der skal ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo/CEO: Vi er tilbage på sporet
2
Pandora: Amerikansk forhandler må nedjustere efter svagt kvartal - NY
3
Novo-chef er bekymret for fremtiden grundet diabetesepidemi - citat
4
Novo planlægger fase 3-udviklingsprogram med subkutan Semaglutid - NY
5
Vindindustriens reaktion på prispres vil være i fokus på konference

Relaterede aktiekurser

AroCell AB (publ) 4,90 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. november 2017 02:37:56
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171108.1 - EUROWEB6 - 2017-11-22 02:37:56 - 2017-11-22 02:37:56 - 1 - Website: OKAY